YLYijun Lin

Yijun Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yijun Lin has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Ruiying Wang

    Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine Fujian Branch of National Clinical Research Center for Cardiovascular Diseases Xiamen University Xiamen 361016 China

    2 shared publications
  • Shuying Wang

    CAS Key Laboratory of Nutrition Metabolism and Food Safety Shanghai Institute of Nutrition and Health University of Chinese Academy of Sciences Chinese Academy of Sciences Shanghai 200031 China

    2 shared publications
  • Binbin Liu

    Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine Fujian Branch of National Clinical Research Center for Cardiovascular Diseases Xiamen University Xiamen 361016 China

    1 shared publication
  • Cuilian Dai

    Xiamen Cardiovascular Hospital School of Medicine Xiamen University Xiamen China

    1 shared publication
  • Jing Yu

    Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine Fujian Branch of National Clinical Research Center for Cardiovascular Diseases Xiamen University Xiamen 361016 China

    1 shared publication
  • Nawsher Wan

    Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine Fujian Branch of National Clinical Research Center for Cardiovascular Diseases Xiamen University Xiamen 361016 China

    1 shared publication

Latest Publications

  • Open Access

    Lactate‐Activated GPR132‐Src Signal Induces Macrophage Senescence and Aggravates Atherosclerosis Under Diabetes

    by Xiaofeng Ge, Shuying Wang, Zhaokai Li, Jing Yu, Binbin Liu, Ruiying Wang, Shichen Bu, Nawsher Wan, Yan Wang, Cuilian Dai, et al.

    Diabetes is widely acknowledged as a significant risk factor for atherosclerosis, facilitating plaque formation through various mechanisms. Although both conditions are linked to the aging process, the relationship among cellular senescence, diabetes, and atherosclerosis remains inadequately understood. This study presents evidence that elevated glucose levels expedite the progression of atherosclerosis by promoting macrophage senescence. Increased glucose levels are shown to induce senescence in macrophages, which enhances the uptake of oxidized low‐density lipoprotein (ox‐LDL) and facilitates the formation of foam cells. This mechanism is driven by lactate production via glycolysis, which activates the lactate receptor GPR132, thereby promoting macrophage senescence. The activation of GPR132 is implicated in mediating senescence and lipid uptake through Src phosphorylation. The deletion of GPR132 markedly reduces macrophage senescence and atherosclerosis in mouse models. Furthermore, saracatinib, a specific Src inhibitor, has been demonstrated to effectively alleviate diabetic atherosclerosis in experimental settings. In clinical samples, elevated plasma lactate levels and the activation of the GPR132‐Src pathway in peripheral blood mononuclear cells (PBMCs) are positively associated with coronary stenosis. These findings propose a potential mechanism through which diabetes accelerates atherosclerosis via the lactate‐GPR132‐Src pathway, underscoring macrophage senescence as a pivotal target in the context of diabetic atherosclerosis.


  • Open Access

    Short‐Term Statin Therapy Induces Hepatic Insulin Resistance Through HNF4α/PAQR9/PPM1α Axis Regulated AKT Phosphorylation

    by Yijun Lin, Shuying Wang, Zixuan Li, Yuling Zhou, Ruiying Wang, Yan Wang, Yan Chen

    Statins, the first‐line medication for dyslipidemia, are linked to an increased risk of type 2 diabetes. But exactly how statins cause diabetes is yet unknown. In this study, a developed short‐term statin therapy on hyperlipidemia mice show that hepatic insulin resistance is a cause of statin‐induced diabetes. Statin medication raises the expression of progesterone and adiponectin receptor 9 (PAQR9) in liver, which inhibits insulin signaling through degradation of protein phosphatase, Mg2+/Mn2+ dependent 1 (PPM1α) to activate ERK pathway. STIP1 homology and U‐box containing protein 1 (STUB1) is found to mediate ubiquitination of PPM1α promoted by PAQR9. On the other hand, decreased activity of hepatocyte nuclear factor 4 alpha (HNF4α) seems to be the cause of PAQR9 expression under statin therapy. The interventions on PAQR9, including deletion of PAQR9, caloric restriction and HNF4α activation, are all effective treatments for statin‐induced diabetes, while liver specific over‐expression of PPM1α is another possible tactic. The results reveal the importance of HNF4α‐PAQR9‐STUB1‐PPM1α axis in controlling the statin‐induced hepatic insulin resistance, offering a fresh insight into the molecular mechanisms underlying statin therapy.